Intech Investment Management LLC raised its stake in shares of Balchem Co. (NASDAQ:BCPC - Free Report) by 170.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 23,258 shares of the basic materials company's stock after purchasing an additional 14,647 shares during the quarter. Intech Investment Management LLC owned 0.07% of Balchem worth $3,791,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently added to or reduced their stakes in BCPC. State Street Corp lifted its position in shares of Balchem by 1.0% during the third quarter. State Street Corp now owns 1,234,226 shares of the basic materials company's stock worth $217,224,000 after purchasing an additional 12,006 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Balchem by 3.1% during the 3rd quarter. Geode Capital Management LLC now owns 928,904 shares of the basic materials company's stock worth $163,514,000 after buying an additional 27,979 shares in the last quarter. Geneva Capital Management LLC lifted its holdings in Balchem by 5.1% during the 4th quarter. Geneva Capital Management LLC now owns 819,746 shares of the basic materials company's stock worth $133,615,000 after buying an additional 39,877 shares in the last quarter. FMR LLC boosted its position in Balchem by 944.3% in the 3rd quarter. FMR LLC now owns 497,495 shares of the basic materials company's stock valued at $87,559,000 after buying an additional 449,854 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Balchem by 1.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 458,986 shares of the basic materials company's stock valued at $80,782,000 after buying an additional 7,721 shares during the period. 87.91% of the stock is owned by institutional investors and hedge funds.
Balchem Trading Up 2.1 %
NASDAQ BCPC traded up $3.35 during trading on Monday, reaching $164.52. 248,600 shares of the stock traded hands, compared to its average volume of 114,088. The stock's 50-day moving average price is $164.71 and its 200 day moving average price is $169.40. The company has a quick ratio of 1.16, a current ratio of 1.99 and a debt-to-equity ratio of 0.19. The firm has a market cap of $5.35 billion, a price-to-earnings ratio of 41.86, a price-to-earnings-growth ratio of 4.41 and a beta of 0.63. Balchem Co. has a fifty-two week low of $137.69 and a fifty-two week high of $186.03.
Balchem (NASDAQ:BCPC - Get Free Report) last released its quarterly earnings data on Friday, February 21st. The basic materials company reported $1.03 EPS for the quarter, missing analysts' consensus estimates of $1.11 by ($0.08). The firm had revenue of $240.00 million during the quarter, compared to the consensus estimate of $239.96 million. Balchem had a net margin of 13.47% and a return on equity of 11.37%. Analysts predict that Balchem Co. will post 4.64 EPS for the current year.
Wall Street Analysts Forecast Growth
Several equities analysts have recently issued reports on BCPC shares. HC Wainwright reaffirmed a "buy" rating and set a $190.00 price target on shares of Balchem in a research note on Monday, February 24th. Sidoti upgraded shares of Balchem to a "hold" rating in a research report on Tuesday, February 25th. Finally, StockNews.com downgraded shares of Balchem from a "buy" rating to a "hold" rating in a research note on Tuesday, February 25th.
Get Our Latest Stock Report on Balchem
Balchem Company Profile
(
Free Report)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
See Also
Before you consider Balchem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Balchem wasn't on the list.
While Balchem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
